What We Do

Aiding customers and Collaborators in the development of Pharmaceuticals

IsoTherapeutics Group is a radiopharmaceutical development company that launched R&D services in 2005 to aid customers and collaborators in the development of pharmaceuticals. The company has earned a solid reputation in radiochemistry, radiolabeling, and process/product development.

IsoTherapeutics Group has recently enhanced its capabilities to help customers with cGMP radiopharmaceutical manufacturing for clinical trials. This helps ensure seamless development of products from research to clinical trial-stage manufacturing.

Work With Us

A variety of ways we work with our customers.

Usually, we perform fee-for-service early stage R&D meeting agreed upon deliverables. We are very flexible and are open to a variety of business models in which we can participate.

Our range of services include helping customers/partners with early stage research from proof of concept for a new chemistry or drug molecule through making of the drug in a cGMP facility for preclinical studies. These services include:


100+ years of collective experience

The company also plays an advisory role based on its 100+ years of collective experience. The company works with customers in a variety ways and engages with customers every step of the way with the final goal being reduction of costs and shortening of the time to clinical trial.

Our Clients & Partners

In the company’s short history, IsoTherapeutics has been able to serve a variety of customers including:

Got a Project? Let's Schedule An Appointment

Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics

Melbourne (Australia) – 27 February 2024. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based in Angleton, Texas. Founded in 2005, IsoTherapeutics is a privately held, commercial-stage company, which provides radiochemistry and bioconjugation development and contract manufacturing services to many companies in the radiopharmaceutical industry, including Telix.
In line with Telix’s continued investment in the vertical integration of supply chain, manufacturing and development capabilities, the acquisition is expected to further enhance Telix’s in-house drug development capabilities. A key driver for the acquisition is to enable Telix to bring select aspects of its development programs in-house, with the goal of reducing cost and time to achieve technical milestones.
The acquisition will also expand Telix’s U.S. manufacturing footprint with a site that includes a GMP1 clean room and production infrastructure suitable for clinical use. The site also has extensive capacity to process a wide variety of therapeutic isotopes used in Telix’s development portfolio.